Triptans Today: Their Role in Contemporary Migraine Treatment

Day 5 (2025)

Key Questions

What are triptans, and how does a patient decide which one to take?
What are the different routes of administration for triptans?
What is the maximum recommended dosage of triptans within a 24-hour period?
Which medications can be taken with triptans while minimizing interactions and side effects?
What does the term “therapeutic window” mean?
Can triptans be used to treat other headache disorders?
Are triptans safe to use during pregnancy and breastfeeding?
Can children and adolescents safely use triptans?
Are there long-term effects of using triptans for extended periods (e.g., decades)?
Are there any conditions or risk factors that contraindicate triptan use?

Interview Notes

Treatments Mentioned

Almotriptan
Analgesics
Anti-inflammatories
Anti-nausea medication
Benzodiazepines
CGRP small-molecule receptor antagonists (gepants)
Ditans (selective 5HT1F receptor agonists)
Eletriptan
Frovatriptan
Hormonal contraceptives
Lasmiditan (Reyvow)
Naproxen
Naratriptan
Rimegepant (Nurtec ODT, Vydrua)
Rizatriptan
Selective serotonin and norepinephrine reuptake inhibitors (SNRIs)
Selective serotonin reuptake inhibitors (SSRIs)
Sumatriptan
Sumatriptan and naproxen sodium (Treximet)
Triptans
Ubrogepant (Ubrelvy)
Zavegepant (Zavzpret)
Zolmitriptan

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Expert

Patricia Pozo-Rosich, MD, PhD

Head of Neurology Section
Vall d’Hebron Hospital and Institute of Research, Spain

As head of section of the neurology department at Vall d’Hebron University Hospital, and director of the Headache and Neurological Pain Research Group at Vall d’Hebron Institute of Research in Barcelona, Spain, Dr. Pozo-Rosich is one of the leading migraine researchers in Europe. An active leader in the field of international headache medicine, Dr. Pozo-Rosich is passionate about educating patients and clinicians about migraine.

She is the honorary secretary of the International Headache Society, and was previously the coordinator of the Headache Study Group of the Spanish Neurological Society (GECSEN). Additionally, she is the founder of the Spanish-language website MiDolordeCabeza.org. In 2023, she was awarded the Cephalalgia Award for her article “Salivary CGRP Can Monitor the Different Migraine Phases: CGRP (In)dependent Attacks.” She also is a two-time recipient of the Scientific Prize for Headache from the Spanish Neurological Society.